Farnesol inhibits in vitro growth of the Cryptococcus neoformans species complex with no significant changes in virulence-related exoenzymes

Veterinary Microbiology

Volumn 159, Issue 3-4, 2012, Pages 375-380

  Cordeiro, Rossana de Aguiar ^a   Nogueira, George Cândido ^b   Brilhante, Raimunda Sâmia Nogueira ^a   Teixeira, Carlos Eduardo Cordeiro ^a   Mourão, Charles Ielpo ^a   Castelo Branco, Débora de Souza Collares Maia ^a   Paiva, Manoel de Araújo Neto ^a,b   Ribeiro, Joyce Fonteles ^a   Monteiro, André Jalles ^a   Sidrim, José Júlio Costa ^a   Rocha, Marcos Fábio Gadelha ^a,b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b STATE UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Cryptococcus neoformans species complex; Farnesol; Minimum inhibitory concentration; Phospholipases; Proteases

Indexed keywords

AMPHOTERICIN B; FARNESOL; FLUCONAZOLE; PHOSPHOLIPASE; PROTEINASE; VIRULENCE FACTOR;

ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; ENZYME ACTIVITY; FUNGAL STRAIN; FUNGAL VIRULENCE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANIMALS; COLUMBIDAE; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FARNESOL; FECES; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDE HYDROLASES; PHOSPHOLIPASES; VIRULENCE; VIRULENCE FACTORS;

CANDIDA; CANDIDA ALBICANS; CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS; PARACOCCIDIOIDES BRASILIENSIS;

EID: 84865655992     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2012.04.008     Document Type: Article

References (38)

1. Bien C.M., Chang Y.C., Nes W.D., Kwon-Chung K.J., Espenshade P.J. Cryptococcus neoformans site-2 protease is required for virulence and survival in the presence of azole drugs. Mol. Microbiol. 2009, 74:672-690.
2. Bovers M., Hagen F., Boekhout T. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev. Iberoamer. Micol. 2008, 25:4-12.
3. Brilhante R.S.N., Paiva M.A.N., Sampaio C.M.S., Teixeira C.E.C., Castelo-Branco D.S.C.M., Leite J.J.G., Moreira C.A., Silva L.P., Cordeiro R.A., Monteiro A.J., Sidrim J.J.C., Rocha M.F.G. Yeasts from Macrobrachium amazonicum: a focus on antifungal susceptibility and virulence factors of Candida spp. FEMS Microbiol. Ecol. 2011, 76:268-277.
4. Brilhante R.S.N., Valente L.G.A., Rocha M.F.G., Bandeira T.J.P.G., Cordeiro R.A., Lima R.A.C., Leite J.J.G., Ribeiro J.F., Pereira J.F., Castelo-Branco D.S.C.M., Sidrim J.J.C. Sesquiterpene farnesol contributing to increased susceptibility to β-lactams in strains of Burkholderia pseudomallei. Antimicrob. Agents Chemother. 2012, 10.1128/AAC.05885-11.
5. Cenci E., Francisci D., Belfiori B., Pierucci S., Baldelli F., Bistoni F., Vecchiarelli A. Tipranavir exhibits different effects on opportunistic pathogenic fungi. J. Infect. 2008, 56:58-64.
6. Chayakulkeeree M., Johnston S.A., Oei J.B., Lev S., Williamson P.R., Wilson C.F., Zuo X., Leal A.L., Vainstein M.H., Meyer W., Sorrell T.C., May R.C., Djordjevic J.T. SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans. Mol. Microbiol. 2011, 80:1088-1101.
7. Chen L., Blank E.S., Casadevall A. Extracellular proteinase activity of Cryptococcus neoformans. Clin. Diagn. Lab. Immunol. 1996, 3:570-574.
8. Chong H.S., Dagg R., Malik R., Chen S., Carter D. In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J. Clin. Microbiol. 2010, 48:4115-4120.
9. CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts 2008, Clinical and Laboratory Standards Institute, Wayne, PA, (M27-A3). 3rd ed.
10. Cordeiro R.A., Costa A.K.F., Brilhante R.S.N., Lima R.A.C., Castelo-Branco D.S.C.M., Ribeiro J.F., Monteiro A.J., Rocha F.A.C., Sidrim J.J.C., Rocha M.F.G. PCR-REA as an important tool for the identification of Cryptococcus neoformans and Cryptococcus gattii from human and veterinary sources. Vet. Microbiol. 2011, 154:180-184.
11. Costa A.K.F., Sidrim J.J.C., Cordeiro R.A., Brilhante R.S.N., Monteiro A.J., Rocha M.F.G. Urban pigeons (Columba livia) as a potential source of pathogenic yeast: a focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. Mycopathologia 2010, 169:207-213.
12. Derengowski L.S., De-Souza-Silva C., Braz S.V., Mello-De-Sousa T.M., Báo S.N., Kyaw C.M., Silva-Pereira I. Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on Paracoccidioides brasiliensis growth and morphogenesis. Ann. Clin. Microbiol. Antimicrob. 2009, 8:13.
13. Hagen F., Illnait-Zaragozi M.T., Bartlett K.H., Swinne D., Geertsen E., Klaassen C.H., Boekhout T., Meis J.F. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob. Agents Chemother. 2010, 54:5139-5145.
14. Hisajima T., Maruyama N., Tanabe Y., Ishibashi H., Yamada T., Makimura K., Nishiyama Y., Funakoshi K., Oshima H., Abe S. Protective effects of farnesol against oral candidiasis in mice. Microbiol. Immunol. 2008, 52:327-333.
15. Hornby J.M., Jensen E.C., Lisec A.D., Tasto J.J., Jahnke B., Shoemaker R., Dussault P., Nickerson K.W. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbiol. 2001, 67:2982-2992.
16. Hornby J.M., Nickeerson K.W. Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob. Agents Chemother. 2004, 48:2305-2307.
17. Iqbal N., DeBess E.E., Wohrle R., Sun B., Nett R.J., Ahlquist A.M., Chiller T., Lockhart S.R. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J. Clin. Microbiol. 2010, 48:539-544. Cryptococcus gattii Public Health Working Group.
18. Jabra-Rizk M.A., Shirtliff M., James C., Meiller T. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance. FEMS Yeast Res. 2006, 6:1063-1073.
19. Jin J., Zhang J.Y., Guo N., Sheng H., Li L., Liang J.C., Wang X.L., Li Y., Liu M.Y., Wu X.P., Yu L. Farnesol, a potential efflux pump inhibitor in Mycobacterium smegmatis. Molecules 2010, 15:7750-7762.
20. Kronstad J.W., Attarian R., Cadieux B., Choi J., D'Souza C.A., Griffiths E.J., Geddes J.M.H., Hu G., Jung W.H., Kretschmer M., Saikia S., Wang J. Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat. Rev. Microbiol. 2011, 9:193-203.
21. Kwon-Chung K.J., Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans?. FEMS Yeast Res. 2006, 6:574-587.
22. Langford M.L., Hasim S., Nickerson K.W., Atkin A.L. Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions. Antimicrob. Agents Chemother. 2010, 54:940-942.
23. Lester S.J., Malik R., Bartlett K.H., Duncan C.G. Cryptococcosis: update and emergence of Cryptococcus gattii. Vet. Clin. Pathol. 2011, 40:4-17.
24. Lin X., Heitman J. The biology of the Cryptococcus neoformans species complex. Annu. Rev. Microbiol. 2006, 8:69-105.
25. Liu P., Luo L., Guo J., Liu H., Wang B., Deng B., Long C.A., Cheng Y. Farnesol induces apoptosis and oxidative stress in the fungal pathogen Penicillium expansum. Mycologia 2010, 102:311-318.
26. Ma H., May R.C. Virulence in Cryptococcus species. Adv. Appl. Microbiol. 2009, 67:131-190.
27. Meyer W., Castañeda A., Jackson S., Huynh M., Castañeda E. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg. Infect. Dis. 2003, 9:189-195. IberoAmerican Cryptococcal Study Group.
28. Navarathna D.H.M.L.P., Hornby J.M., Hoerrmann N., Parkhurst A.M., Duhamel G.E., Nickerson K.W. Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. J. Antimicrob. Chemother. 2005, 56:1156-1159.
29. Pammi M., Liang R., Hicks J.M., Barrish J., Versalovic J. Farnesol decreases biofilms of Staphylococcus epidermidis and exhibits synergy with nafcillin and vancomycin. Pediatr. Res. 2011, 70:578-583.
30. Price M.F., Wilkinson I.D., Gentry L.O. Plate method for detection of phospholipase activity of Candida albicans. Sabouraudia 1982, 22:201-207.
31. Rossignol T., Logue M.E., Reynolds K., Grenon M., Lowndes N.F., Butler G. Transcriptional response of Candida parapsilosis following exposure to farnesol. Antimicrob. Agents Chemother. 2007, 51:2304-2312.
32. Sharma M., Prasad R. The Quorum-Sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans. Antimicrob. Agents Chemother. 2011, 55:4834-4843.
33. Semighini C.P., Murray N., Harris S.D. Inhibition of Fusarium graminearum growth and development by farnesol. FEMS Microbiol. Lett. 2008, 279:259-264.
34. Shirtliff M.E., Krom B.P., Meijering R.A., Peters B.M., Zhu J., Scheper M.A., Harris M.L., Jabra-Rizk M.A. Farnesol-induced apoptosis in Candida albicans. Antimicrob. Agents Chemother. 2009, 53:2392-2401.
35. Sidrim J.J.C., Maia D.C.B.S.C., Brilhante R.S.N., Soares G.D.P., Cordeiro R.A., Monteiro A.J., Rocha M.F.G. Candida species isolated from the gastrointestinal tract of cockatiels (Nymphicus hollandicus): in vitro antifungal susceptibility profile and phospholipase activity. Vet. Microbiol. 2010, 145:324-328.
36. Trilles L., Fernandez-Torres B., Lazera M.S., Wanke B., Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 2004, 42:4815-4817.
37. Trilles L., Meyer W., Wanke B., Guarro J., Lazéra M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med. Mycol. 2011, 50:328-332.
38. Weber K., Schulz B., Ruhnke M. The quorum-sensing molecule E,E-farnesol - its variable secretion and its impact on the growth and metabolism of Candida species. Yeast 2010, 27:727-739.